|
Malignant neoplasm of breast
|
0.370 |
PosttranslationalModification
|
disease |
BEFREE |
Breast cancer cell-induced tyrosine phosphorylation of VE-cad was mediated by activation of the H-Ras/Raf/MEK/ERK signaling cascade and depended on the phosphorylation of endothelial myosin light chain (MLC).
|
22833667 |
2012 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression.
|
23216791 |
2012 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
In this study we aimed to further validate the utility of CDH5 as a biomarker for breast cancer progression.
|
27010749 |
2016 |
|
Malignant neoplasm of breast
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that factors released by breast cancer cells are able to upregulate Twist, Slug, and Snail expression in EC, which in turn downregulate the activity of the VE-cadherin promoter.
|
19046938 |
2009 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
|
10969774 |
2000 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
Frozen sections from breast cancer primary tumours (tumour n = 114, background n = 30) were immunostained with VE-cadherin, factor VIII and PECAM-1 antibodies and microvessel number was assessed.
|
15810954 |
2005 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
Experimental expression of fluorescence-tagged VE-cadherin (VE-EGFP) in undifferentiated, fibroblastoid and E-cadherin-negative MDA-231 (MDA-VE-EGFP) as well as in differentiated E-cadherin-positive MCF-7 human breast cancer cell lines (MCF-VE-EGFP), respectively, displayed differentiation-dependent functional differences.
|
29143117 |
2018 |
|
Breast Carcinoma
|
0.370 |
PosttranslationalModification
|
disease |
BEFREE |
Breast cancer cell-induced tyrosine phosphorylation of VE-cad was mediated by activation of the H-Ras/Raf/MEK/ERK signaling cascade and depended on the phosphorylation of endothelial myosin light chain (MLC).
|
22833667 |
2012 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Experimental expression of fluorescence-tagged VE-cadherin (VE-EGFP) in undifferentiated, fibroblastoid and E-cadherin-negative MDA-231 (MDA-VE-EGFP) as well as in differentiated E-cadherin-positive MCF-7 human breast cancer cell lines (MCF-VE-EGFP), respectively, displayed differentiation-dependent functional differences.
|
29143117 |
2018 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
In this study we aimed to further validate the utility of CDH5 as a biomarker for breast cancer progression.
|
27010749 |
2016 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
|
10969774 |
2000 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Frozen sections from breast cancer primary tumours (tumour n = 114, background n = 30) were immunostained with VE-cadherin, factor VIII and PECAM-1 antibodies and microvessel number was assessed.
|
15810954 |
2005 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that factors released by breast cancer cells are able to upregulate Twist, Slug, and Snail expression in EC, which in turn downregulate the activity of the VE-cadherin promoter.
|
19046938 |
2009 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression.
|
23216791 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, VE-cadherin expression had no effect on tumor cell proliferation in monocultures while co-culturing with endothelial cells enhanced tumor cell proliferation due to integration of the tumor cells into monolayer where they form VE-cadherin-mediated cell contacts with the endothelium.
|
29143117 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Accordingly, VE-cadherin gene inactivation by antisense morpholino oligonucleotide injection inhibits tumor neovascularization without affecting the development of intersegmental and subintestinal vessels.
|
17409396 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RF-assisted gadofullerene nanoparticles induces rapid tumor vascular disruption by down-expression of tumor vascular endothelial cadherin.
|
29459323 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We report that fibrin-mediated angiogenesis was inhibited and tumor growth delayed following postnatal deletion of Tgfbr2 in the endothelium of Cdh5-CreERT2 Tgfbr2fl/fl mice (Tgfbr2iECKO mice).
|
30855280 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Extensive in vitro and in vivo lineage analyses, including single cell clonal studies, further show that a subpopulation of the CD133(+) stem-like cell fraction is multipotent and capable of differentiation along tumour and endothelial lineages, possibly via an intermediate CD133(+)/CD144(+) progenitor cell.
|
21102433 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We observed a decrease of tumor myeloid cell Shb mRNA in the tamoxifen treated Cdh5-CreERT2/Shb<sup>flox/flox</sup> mice, which was not present when the mice had undergone a preceding bone marrow transplantation using wild type bone marrow.
|
31101877 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Frozen sections from breast cancer primary tumours (tumour n = 114, background n = 30) were immunostained with VE-cadherin, factor VIII and PECAM-1 antibodies and microvessel number was assessed.
|
15810954 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VE-cadherin/CDH5 plays a role in tumor-associated angiogenesis.
|
20457567 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis.
|
15735710 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, inactivation of Cdh1 and Cdh5 is likely to cooperate with the loss of p53, suggesting a possible tumor suppressive function of these genes in mammary carcinogenesis.
|
17327688 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
|
28655790 |
2017 |